AROA BIOSURGERY LIMITED — Investor Relations & Filings

Aroa Biosurgery Limited specializes in the development and commercialization of regenerative medical devices for wound healing and soft tissue reconstruction. The company’s core technology is the AROA ECM platform, a proprietary extracellular matrix derived from ovine forestomach tissue. This scaffold-based technology is engineered to facilitate host cell infiltration and promote new blood vessel formation, supporting the body's natural healing process. The product portfolio includes Endoform for chronic and acute wound management, Myriad for complex surgical applications, and Symphony for skin substitute procedures. Additionally, the company manufactures the Ovitex and Ovitex PRS reinforced tissue matrices for hernia repair and breast reconstruction. These solutions target clinical needs in advanced wound care and surgical specialties by providing biological scaffolds that integrate into host tissue.